Mereo BioPharma Group plc

**Signal Note: EcoR1 Capital Initiates $3.3M Position in Mereo BioPharma** EcoR1's entry into MREO likely reflects conviction in the company's lead program BPS804 (anti-LoxL2 monoclonal antibody) for idiopathic pulmonary fibrosis (IPF), which showed clinically meaningful FVC decline reduction in Phase 2b data and is advancing toward Phase 3 initiation expected in 2024-2025. The $3.3M stake (~7.9M shares at ~$0.42/share) signals belief in near-term catalysts, though MREO's capital structure and cash runway should be monitored closely given typical biotech cash burn rates.